ARCHIVES

Perifosine Fails Primary Endpoint, Zentaris CEO Explores Options

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation

May 30, 2014

825,000 Pounds of Yew Bark Clleced in ’91 For 10,000 Patients

March 13, 1992

Management Survey Finds Problems At ACS, Advises Change

July 3, 1992

Breast Cancer Task Force Hears Update on Research, Abstract Excerpter

September 19, 1980

House Subcommittee allocates $11.3 Billion To NIH, $2.1 Bil. To NCI

June 17, 1994

Chabner On Taxol, NSABP: “Makes You Lose Confidence In The Political Process”

May 12, 1995